Can IL-23 be a good target for ulcerative colitis?

Mariangela Allocca; Federica Furfaro; Gionata Fiorino; Daniela Gilardi; Silvia D'Alessio; Silvio Danese

doi:10.1016/j.bpg.2018.05.016

Can IL-23 be a good target for ulcerative colitis?

Mariangela Allocca, Federica Furfaro, Gionata Fiorino, Daniela Gilardi, Silvia D'Alessio, Silvio Danese

Istituto Clinico Humanitas

Research output: Contribution to journal › Review article › peer-review

Abstract

A considerable percentage of patients with ulcerative colitis (UC) do not respond to therapies, including anti-tumor necrosis factor (TNF) drugs and vedolizumab, or lose response over time. Hence the continuing need to find new therapeutic strategies and novel drugs to control this chronic debilitating disease. Increased levels of interleukin (IL)-23 and T helper (Th) 17 cell cytokines have been found in intestinal mucosa, plasma, and serum of patients with inflammatory bowel disease (IBD). IL23-blocking has been shown to reduce the severity of inflammation in experimental colitis. Lastly, ustekinumab, a monoclonal antibody (mAb) to the p40 subunit of IL-12 and IL-23, has showed good efficacy and safety profile in patients with Crohn's disease (CD). This review aims to discuss the available data on IL-23 and Th17 cell pathways in UC, in order to define the role of IL-23 as possible target for the treatment of UC.

Original language	English
Pages (from-to)	95-102
Number of pages	8
Journal	Best Practice and Research: Clinical Gastroenterology
Volume	32-33
DOIs	https://doi.org/10.1016/j.bpg.2018.05.016
Publication status	Published - Feb 1 2018

Keywords

Crohn's disease
IL-23
Inflammatory bowel disease
Monoclonal antibody anti-IL23
Th17 cell pathway cytokines
Ulcerative colitis

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1016/j.bpg.2018.05.016

Cite this

@article{a6dfd46d4e694af7a2ec8bf6ddebe795,

title = "Can IL-23 be a good target for ulcerative colitis?",

abstract = "A considerable percentage of patients with ulcerative colitis (UC) do not respond to therapies, including anti-tumor necrosis factor (TNF) drugs and vedolizumab, or lose response over time. Hence the continuing need to find new therapeutic strategies and novel drugs to control this chronic debilitating disease. Increased levels of interleukin (IL)-23 and T helper (Th) 17 cell cytokines have been found in intestinal mucosa, plasma, and serum of patients with inflammatory bowel disease (IBD). IL23-blocking has been shown to reduce the severity of inflammation in experimental colitis. Lastly, ustekinumab, a monoclonal antibody (mAb) to the p40 subunit of IL-12 and IL-23, has showed good efficacy and safety profile in patients with Crohn's disease (CD). This review aims to discuss the available data on IL-23 and Th17 cell pathways in UC, in order to define the role of IL-23 as possible target for the treatment of UC.",

keywords = "Crohn's disease, IL-23, Inflammatory bowel disease, Monoclonal antibody anti-IL23, Th17 cell pathway cytokines, Ulcerative colitis",

author = "Mariangela Allocca and Federica Furfaro and Gionata Fiorino and Daniela Gilardi and Silvia D'Alessio and Silvio Danese",

year = "2018",

month = feb,

day = "1",

doi = "10.1016/j.bpg.2018.05.016",

language = "English",

volume = "32-33",

pages = "95--102",

journal = "Bailliere's Best Practice and Research in Clinical Gastroenterology",